News | November 14, 2022
Aurobindo Pharma Q2 FY23 revenue down 3.4%
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
ASG is accelerating its doctor-led mission to enhance the quality of care, deliver eye care for all, and improve quality of life across India.
Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.
KDAH Indore is a super-speciality, patient-centric, tertiary-care institution located in the Nipaniya area of Indore.
The company is committed to addressing the observations at the earliest, and gaining approval for injectable manufacturing for the US
The observation is procedural in nature and the company will address the observation within stipulated timelines.
Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
NABH shall encourage and provide assistance in onboarding their accredited/certified facilities on ABDM’s Health Facility Registry
Since FY 2020 till FY 2022, the organisation has reduced energy consumption by 9.2%
Subscribe To Our Newsletter & Stay Updated
